Browse Drug Recalls
383 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 383 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 383 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jun 2, 2015 | Estradiol 8 mg, Sterile Pellet, The Compounding Pharmacy of America, Inc., Kn... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Tri-Mix MEDIUM (15 mg/0.5 mg/5 mcg) Injectable, The Compounding Pharmacy of A... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Lipovicine Modified II Injectable, Multi-Dose Vial, Sterile, Room Temperature... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Estradiol 25 mg, Sterile Pellet, The Compounding Pharmacy of America, Inc., K... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Tri-Mix Super Injectable, Multi-Dose Vial, Sterile, Keep Frozen, The Compound... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Tri-Mix (6.9/0.575/39.375) Injectable, The Compounding Pharmacy of America, K... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Baclofen 2,500 mcg/ml Intrathecal Solution, Sterile-Preservative Free, The Co... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Tri-Mix (17.7 mg/0.59 mg/6 mcg) Injectable, Sterile, Keep Frozen, The Compou... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | HCG 1,000 IU/ml Injection, Multi-Dose Vial, Sterile, Refrigerate, 23 DAY KIT,... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Acetylcysteine 100 mg/ml Injectable, Multi-Dose Vial, Sterile, Refrigerate, T... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Mitomycin 40 mg/50 ml Sodium Chloride 0.9% Injection, Single Dose Syringe, Th... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Morphine 50 mg/ml + Clonidine 200 mcg/ml Solution, Sterile-Preservative Free,... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hydromorphone 20 mg/ml Solution, Sterile-Preservative Free, The Compounding P... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | L-Arginine 100 mg/ml Injectable, Multi-Dose Vial, Sterile, Refrigerate, The C... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Phosphatidylcholine 0.1% Sodium Deoxycholate 0.089% Injection, Vial, Sterile,... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Quad-Mix 4 Injectable, Multi-Dose Vial, Sterile, Keep Frozen, The Compounding... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Morphine 12.5 mg/ml Solution, Sterile-Preservative Free,The Compounding Pharm... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Morphine 25 mg/ml + Bupivacaine 20 mg/ml + Clonidine 2,000 mcg/ml Solution, S... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | PGE 2 (Alprostadil) 100 mcg/ml, Sterile, Keep Frozen, The Compounding Pharmac... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | B-Complex 100 mg/ml Injection, Sterile, Refrigerate, The Compounding Pharmacy... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Tri-Mix AT-6 (60 mg/4 mg/0.3 mg) Injectable, The Compounding Pharmacy of Ame... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hydromorphone 80 mg/ml + Fentanyl 15,000 mcg/ml + Bupivacaine 30 mg/ml + Bacl... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Testosterone 12.5 mg, Sterile Pellet, The Compounding Pharmacy of America, Kn... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Morphine 25 mg/ml + Bupivacaine 30 mg/ml + Clonidine 200 mcg/ml Solution, Ste... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Fentanyl 2,000 mcg/ml + Bupivacaine 20 mg/ml Intrathecal Solution, Sterile - ... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hydromorphone 80 mg/ml + Bupivacaine 10 mg/ml + Clonidine 1,000 mcg/ml, Baclo... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hydromorphone 50 mg/ml + Fentanyl 3,000 mcg/ml + Bupivacaine 20 mg/ml Intrath... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hyaluronic Acid Sodium 28 mg/ml + Lidocaine HCl 3 mg/ml Injection, ml Syringe... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Morphine 60 mg/ml Solution, Sterile-Preservative Free, The Compounding Pharma... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Hydromorphone 30 mg/ml Solution, Sterile-Preservative Free, The Compounding P... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | HCG 1,250 IU/ml Injection, Multi-Dose Vial, Sterile, Refrigerate The Compound... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | Testosterone 20 mg, Sterile Pellet, The Compounding Pharmacy of America, Knox... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
| Jun 2, 2015 | HCG 1,100 IU/ml Injection, Multi-Dose Vial, Sterile, Refrigerate The Compound... | Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting pr... | Class II | The Compounding Pharmacy of America |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.